Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
R&D
Page 4
R&D
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment
Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma
Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment
Ipsen and Biomunex enter exclusive global licensing agreement for MAIT cell...
5th December 2024
Arrowhead forms agreement with Sarepta for multiple clinical and preclinical programs...
2nd December 2024
GSK to acquire CMG1A46 from Chimagen Biosciences, expanding immunology pipeline
31st October 2024
Dyno Therapeutics forms partnership with Roche to advance AAV gene therapy...
30th October 2024
ViaNautis Bio signs agreement with Lilly to develop novel products delivering...
29th October 2024
AbbVie and Gedeon Richter to discover and develop novel targets for...
25th October 2024
Cancer Research UK and KisoJi Biotechnology collaborate to advance the first...
24th October 2024
Avacta and Tempus to advance AI-driven drug development in oncology
24th October 2024
Editas Medicine and Genevant Sciences to develop novel MRNA-LNP gene editing...
24th October 2024
GSK and Cambridge University form new five-year collaboration in kidney and...
23rd October 2024
1
...
3
4
5
...
54
Page 4 of 54
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...